Search

Your search keyword '"Cho, Eun-Kyung"' showing total 672 results

Search Constraints

Start Over You searched for: Author "Cho, Eun-Kyung" Remove constraint Author: "Cho, Eun-Kyung"
672 results on '"Cho, Eun-Kyung"'

Search Results

1. The forb-flex method for odd coloring and proper conflict-free coloring of planar graphs

2. On the interval coloring impropriety of graphs

3. Domination of subcubic planar graphs with large girth

4. Independent domination versus packing in subcubic graphs

5. Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial

7. Brooks-type theorems for relaxations of square colorings

8. Relaxation of Wegner's Planar Graph Conjecture for maximum degree 4

9. Proper conflict-free coloring of sparse graphs

10. Odd coloring of sparse graphs and planar graphs

11. Independent domination of graphs with bounded maximum degree

12. Tight bound for independent domination of cubic graphs without $4$-cycles

14. On independent domination of regular graphs

15. Improvements on Hippchen's Conjecture

16. Decomposing planar graphs into graphs with degree restrictions

17. The strong clique number of graphs with forbidden cycles

18. Partitioning planar graphs without $4$-cycles and $5$-cycles into bounded degree forests

19. Generalized list colouring of graphs

21. On induced saturation for paths

24. Sharp conditions for the existence of an even $[a,b]$-factor in a graph

26. A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors

27. A spectral characterisation of t-designs and its applications

31. Ginsenoside Rg3 restores hepatitis C virus–induced aberrant mitochondrial dynamics and inhibits virus propagation

32. A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer...

33. A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation–Positive NSCLC Patients

35. 797 Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2 negative metastatic breast cancer

36. Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial

38. Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1–2 study

40. Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset

42. Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial

44. Table S2 from Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer

Catalog

Books, media, physical & digital resources